Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Acetyl-L-Leucine in Ataxia-Telangiectasia (A-T)
NCT06673056Phase 3Active, not recruiting
- Sponsor
- IntraBio
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in ataxia-telangiectasia (AT) comparing N-acetyl-L-leucine (IB1001) with Placebo comparator (2 arms). Primary endpoint: Scale for the Assessment and Rating of Ataxia at 24 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
levacetylleucine
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT06673056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673056.